Last updated 15 September 2026 · Originally published 12 November 2021
Can CBD shrink tumors? In cells and animals, CBD can damage cancer cells and slow some experimental tumors. A handful of uncontrolled human reports — including two lung-cancer case reports — describe tumors shrinking while people were using CBD or cannabinoid oils. But one of those oils contained substantial THC and THCA as well as CBD, and no completed controlled trial has shown that CBD shrinks tumors or treats cancer in people. All of that is true at once, and understanding how it fits together matters more than any single headline.
What “CBD kills cancer cells” actually means
Search for CBD and cancer and you will find real, published research showing CBD triggers cell death, blocks cell division, or interferes with tumor growth pathways — in cells growing in a dish, or in mice. This research is genuine and not fringe. It is also overwhelmingly this kind of study: in one 2025 review of the lung cancer evidence specifically, 17 of the 19 included studies were conducted in cells or animals, with two case reports the only human data. That matters because many substances damage isolated cancer cells without becoming safe or effective medicines, and the gap between “affects cells in a lab” and “treats a disease in a person” is where most promising cancer compounds in history have failed. Laboratory findings are a reason to run the next experiment. They are not a result you can act on.
The two human cases — and their limits
Two published lung-cancer case reports are repeatedly cited as the human evidence here. In one, published in 2019, a patient self-administering CBD oil saw their tumor regress on repeated scans. In a second, a woman in her eighties with lung cancer who had declined conventional treatment saw the maximum diameter of her tumor shrink from 41 mm to 10 mm — a 76% reduction in that measurement, not in the tumor’s overall volume — over two and a half years, documented on imaging. That second case is also where the label “CBD oil” breaks down under scrutiny: according to the supplier, the product she used contained 20.05% CBD, 19.5% THC and 23.8% THCA, and its actual contents were never independently verified. Whatever happened to her tumor cannot be attributed specifically to CBD, because it was only one of three major cannabinoids reportedly present.
Both reports are real, published and worth treating as reasons for further research. But a 2025 review of this evidence classified both as being at “critical risk of bias.” Neither had a comparison group, and neither can rule out spontaneous regression, inaccurate product information, or other explanations. Both patients, notably, had declined chemotherapy and radiotherapy — so in neither case is there a conventional treatment to weigh the outcome against. Spontaneous tumor regression without any treatment at all is rare but real and has been documented in cancer patients who used nothing at all. Two people are not enough to distinguish “the CBD did this” from “this occasionally happens” or “this specific tumor type behaved unusually.” Neither report’s authors claimed otherwise; the overreach happens later, in how the finding gets repeated.
What happened when it was actually tested
The gap between those two paths — promising cells, promising anecdotes — is exactly what a controlled trial is for, and cancer researchers have run some. No completed controlled trial has shown that CBD shrinks tumors or improves cancer outcomes. Several have tested whether CBD helps people already living with cancer feel better, which is a different and still important question.
The largest, a 2023 trial of 144 people with advanced cancer in palliative care, gave oral CBD three times a day alongside standard palliative treatment and compared it with placebo, also alongside standard care. CBD did not improve overall symptom burden beyond what standard care already provided. A 2024 trial testing CBD against anxiety before cancer scans, in 50 women with advanced breast cancer, missed its main target too, though anxiety levels were measurably lower a few hours after taking it — a smaller, secondary signal worth further study, not a settled result.
Put together with the wider evidence on cannabis in cancer care, a pattern emerges that the house position on this site keeps landing on: where cannabinoids have a place in cancer supportive care, it is mostly cannabis products containing THC, and even there the ground is narrower than it is sometimes made to sound. The clearest recognised use is chemotherapy-induced nausea and vomiting that persists despite standard anti-nausea medicines. Evidence for THC-CBD sprays in cancer pain is mixed, and CBD alone has not reliably improved cancer pain or overall symptom burden. Nowhere in this picture, for any cannabinoid, is there evidence for treating the disease itself.
What this means if you or someone you love has cancer
None of this makes the underlying science worthless, and none of it means people investigating CBD are being foolish — the laboratory findings are real, and the two case reports are a legitimate reason researchers keep looking. But nothing here supports using CBD instead of, or as a substitute for, cancer treatment recommended by an oncologist. The two people whose stories get told the most both went without conventional treatment, and their outcomes cannot tell you what would have happened to them, or would happen to you, on either path. If you are curious about CBD for symptoms — nausea, sleep, anxiety, appetite — talk to your oncology team first: CBD can affect how the liver processes other drugs, creating potential interactions with some cancer medicines. That conversation, not a bottle bought online, is where this actually starts.
Nothing in this article is medical advice. CBD has not been shown to treat cancer, and no one should delay, refuse or replace cancer treatment recommended by a doctor on the basis of anything in this article or anywhere else online. If you have cancer, talk to your oncologist before starting CBD or any cannabis product.
